Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-20T04:37:52.253Z Has data issue: false hasContentIssue false
  • English
  • Français

Management of Painful Physical Symptoms Associated With Depression and Mood Disorders

Published online by Cambridge University Press:  06 November 2014

Thomas N. Wise ,
Lesley M. Arnold ,
Vladimir Maletic  and
David L. Ginsberg
Get access Rights & Permissions [Opens in a new window]

Abstract

Depression is a common, recurring illness that continues to be underdiagnosed and undertreated in both psychiatric and primary care settings. It is increasingly being recognized that painful physical symptoms, which commonly exist comorbid with depressive disorders, play a role in complicating diagnosis of depression. Patients tend to discuss physical pain with primary care physicians and emotional pain with psychiatrists, often oblivious to the fact that both may be aspects of one disorder. Those who present with somatic complaints are three times less likely to be accurately diagnosed than patients with psychosocial complaints. However, thorough evaluation of mood and anxiety disorders in primary care is sparse due to the limited time primary care physicians can spend with each patient. Better recognition and treatment of both physical and emotional symptoms associated with mood disorders may increase a patient's chance of achieving remission, which is the optimum therapeutic goal.

Abnormalities of serotonin and noradrenaline are strongly associated with depression and are thought to play a role in pain perception. Brain-derived neurotrophic factor, which is increased with antidepressant treatment, appears to influence regulation of mood and perception of pain. Clinical evidence indicates that dual-acting agents may have an advantage in modulating pain over those agents that increase either serotonin or noradrenaline alone. The novel dual-acting agents, such as venlafaxine and duloxetine, are better tolerated than tricyclic antidepressants and monoamine oxidase inhibitors. These agents have demonstrated efficacy in depression and in diabetic neuropathic pain independently. Therefore, unless otherwise stated, all inferences to studies of pain in this monograph refer to neuropathic pain in nondepressed patients.

Type
Research Article
Information
CNS Spectrums , Volume 10 , supplement S19 , December 2005 , pp. 1 - 16
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Murray, CJL, Lopez, AD, eds. The Global Burden of Disease. Boston, MA: Harvard University Press; 1996.Google ScholarPubMed
2. Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. Washington, DC: American Psychiatric Association; 1999.Google Scholar
3. Wells, KB, Stewart, A, Hays, RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262(7):914–919.CrossRefGoogle ScholarPubMed
4. Kessler, RC, Berglund, P, Demler, O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105.Google Scholar
5. Schurman, RA, Kramer, PD, Mitchell, JB. The hidden mental health network. Treatment of mental illness by nonpsychiatrist physicians. Arch Gen Psychiatry. 1985;42(1):89–94.Google Scholar
6. Bridges, KW, Goldberg, DP. Somatic presentation of DSM III psychiatric disorders in primary care. J Psychosom Res. 1985;29(6):563–569.Google Scholar
7. Kirmayer, LJ, Robbins, JM, Dworkind, M, Yaffe, MJ. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry. 1993;150(5):734–741.Google ScholarPubMed
8. Simon, GE, VonKorff, M, Piccinelli, M, Fullerton, C, Ormel, J. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341(18):1329–1335.CrossRefGoogle Scholar
9. Kroenke, K, Jackson, JL, Chamberlin, J. Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcome. Am J Med. 1997;103(5):339–347.Google Scholar
10. Kroenke, K, Spitzer, RL, Williams, JB, et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med. 1994;3(9):774–779.Google Scholar
11. Gerber, PD, Barrett, JE, Barrett, JA, et al. The relationship of presenting physical complaints to depressive symptoms in primary care patients. J Gen Intern Med. 1992;7(2):170–173.CrossRefGoogle ScholarPubMed
12. Watts, CAH. Depresive Disorders in the Community. Bristol, England: John Wirte and Sons; 1996.Google Scholar
13. Von Knorring, L. The experience of pain in depressed patients: a clinical and experimental study. Neuropsychobiology. 1965;1:155–165.CrossRefGoogle Scholar
14. Katon, W, Sullivan, MD. Depression and chronic medical illness. J Clin Psychiatry. 1990;51(suppl):3–11; discussion 12-4.Google Scholar
15. Arnold, LM, Hudson, JI, Hess, EV, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50(3):944–952.Google Scholar
16. Ohayon, MM, Schatzberg, AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry. 2003;60(1):39–47.Google Scholar
17. Wu, LR, Parkerson, GR Jr, Doraiswamy, PM. Health perception, pain, and disability as correlates of anxiety and depression symptoms in primary care patients. J Am Board Fam Pract. 2002;15(3):183–190.Google Scholar
18. Nierenberg, AA, DeCecco, LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):5–9.Google ScholarPubMed
19. Judd, LL, Akiskal, HS, Maser, JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97–108.Google Scholar
20. Paykel, ES, Ramana, R, Cooper, Z, Hayhurst, H, Kerr, J, Barocka, A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171–1180.Google Scholar
21. Bair, MJ, Robinson, RL, Eckert, GJ, Stang, PE, Croghan, TW, Kroenke, K. Impact of pain on depression treatment response in primary care. Psychosom Med. 2004;66(1):17–22.Google Scholar
22. Fava, M, Mallinckrodt, CH, Detke, MJ, Watkin, JG, Wohlreich, MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry. 2004;65(4):521–530.Google Scholar
23. Doraiswamy, PM, Khan, ZM, Donahue, RM, Richard, NE. Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. Am J Geriatr Psychiatry. 2001;9(4):423–428.Google Scholar
1. Kirmayer, LJ, Robbins, JM, Dworkind, M, Yaffe, MJ. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry. 1993;150(5):734–741.Google Scholar
2. McWilliams, LA, Goodwin, RD, Cox, BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. 2004;111(1-2):77–83.Google Scholar
3. Bair, MJ, Robinson, RL, Eckert, GJ, Stang, PE, Croghan, TW, Kroenke, K. Impact of pain on depression treatment response in primary care. Psychosom Med. 2004;66(1):17–22.Google Scholar
4. Gallagher, RM, Verma, S. Managing pain and comorbid depression: A public health challenge. Semin Clin Neuropsychiatry. 1999;4(3):203–220.Google Scholar
5. Basbaum, AI, Fields, HL. Endogenous pain control mechanisms: review and hypothesis. Ann Neurol. 1978;4(5):451–462.Google Scholar
6. Brose, W, Spiegel, D. Neuropsychiatric aspects of pain management. In: Yudofsky, SC, Hales, RE, eds. The American Psychiatric Press Textbook of Neuropsychiatry. Washington, DC: American Psychiatric Press; 1992.Google Scholar
7. Shimizu, E, Hashimoto, K, Okamura, N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54(1):70–75.CrossRefGoogle ScholarPubMed
8. D'Sa, C, Duman, RS. Antidepressants and neuroplasticity. Bipolar Disord. 2002;4(3):183–194.CrossRefGoogle ScholarPubMed
9. Castren, E. Is mood chemistry? Nat Rev Neurosci. 2005;6(3):241–246.Google Scholar
10. Sheline, YI, Wang, PW, Gado, MH, Csernansky, JG, Vannier, MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A. 1996;93(9):3908–3913.CrossRefGoogle ScholarPubMed
11. Hoshaw, BA, Malberg, JE, Lucki, I. Central administration of IGF-I and BD NF leads to long-lasting antidepressant-like effects. Brain Res. 2005;1037(1-2):204–208.Google Scholar
12. Ivy, AS, Rodriguez, FG, Garcia, C, Chen, MJ, Russo-Neustadt, AA. Noradrenergic and serotonergic blockade inhibits BDNF mRNA activation following exercise and antidepressant. Pharmacol Biochem Behav. 2003;75(1):81–88.Google Scholar
13. Duman, RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. 2004;5(1):11–25.Google Scholar
14. Dias, BG, Banerjee, SB, Duman, RS, Vaidya, VA. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology. 2003;45(4):553–563.CrossRefGoogle ScholarPubMed
15. Duric, V, McCarson, KE. Hippocampal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression is decreased in rat models of pain and stress. Neuroscience. 2005;133(4):999–1006.Google Scholar
16. Frasure-Smith, N, Lesperance, F, Talajic, M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91(4):999–1005. Erratum in: Circulation 199824;97(7):708.Google Scholar
17. Lesperance, F, Frasure-Smith, N, Talajic, M, Bourassa, MG. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation. 2002;105(9):1049–1053.CrossRefGoogle ScholarPubMed
18. Nemeroff, CB, Musselman, DL, Evans, DL. Depression and cardiac disease. Depress Anxiety. 1998;8(suppl 1):71–79.Google Scholar
19. Yang, B, Slonimsky, JD, Birren, SJ. A rapid switch in sympathetic neurotransmitter release properties mediated by the p75 receptor. Nat Neurosci. 2002;5(6):539–545.Google Scholar
20. Lynch, ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci. 2001;26:30–36.Google Scholar
21. Goldstein, DJ, Lu, Y, Detke, MJ, Lee, TC, Iyengar, S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1-2):109–118.Google Scholar
22. Fava, M, Mallinckrodt, CH, Detke, MJ, Watkin, JG, Wohlreich, MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry. 2004;65(4):521–530.Google Scholar
23. Fishbain, D. Evidence-based data on pain relief with antidepressants. Ann Med. 2000;32(5):305–316.CrossRefGoogle ScholarPubMed
24. Vrethem, M, Boivie, J, Arnqvist, H, Holmgren, H, Lindstrom, T, Thorell, LH. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain. 1997;13(4):313–323.Google Scholar
25. Sindrup, SH, Jensen, TS. Efficacy of pharmacological measurements of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389–400.Google Scholar
26. Kunz, NR, Goli, V, Entsuah, R, Rudolph, R. Diabetic neuropathic pain management with venlafaxine extended release. Eur Neuropsychopharmacol. 2000;10(3):S389.CrossRefGoogle Scholar
27. Paykel, ES, Ramana, R, Cooper, Z, Hayhurst, H, Kerr, J, Barocka, A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171–1180.Google Scholar
28. Denninger, JW, Mahal, Y, Merens, W, et al. The relationship between somatic symptoms and depression. Presented at: 155th Annual Meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, Pa.Google Scholar
29. Farabaugh, A, Mischoulon, D, Fava, M, et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol. 2005;20(2):87–91.Google Scholar
30. Anderson, IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety. 1998;7(suppl 1):11–7.Google Scholar
31. Nelson, JC, Mazure, CM, Jatlow, PI, Bowers, MB Jr, Price, LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55(3):296–300.Google Scholar
32. Thase, ME, Entsuah, AR, Rudolph, RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–241.Google Scholar
33. Smith, D, Dempster, C, Glanville, J, Freemantle, N, Anderson, I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002;180:396–404.Google Scholar
1. Detke, MJ, Lu, Y, Golstein, DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63(4):308–315.Google Scholar
2. Detke, MJ, Lu, Y, Goldstein, DJ, McNamara, RK, Demitrack, MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatry Res. 2002;36(6):383–390.Google Scholar
3. Detke, MJ, Wiltse, C, Mallinckrodt, CH, McNamara, RK, Demitrack, MA, Bitter, I. Duloxetine in the acute and long term treatment of major depressive disorder: a placebo and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14:457–470.Google Scholar
4. Perahia, D, Pritchett, YL, Lee, TC, Tran, PF. Comparing duloxetine and venlafaxine in the treatment of major depressive disorder using a global benefit-risk approach. Presented at: 45th Annual Meeting of the New Clinical Drug Evaluation Unit; 2005. Boca Raton.Google Scholar
5. Delgado, PL, Brannan, SK, Mallinckrodt, CH, et al. Sexual functioning assessed in 4 double blind placebo and paroxetine controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry. 20005;66:686–692.CrossRefGoogle Scholar
6. Dunner, DL, Goldstein, DJ, Mallinckrodt, C, Lu, Y, Detke, MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003;18(2):53–61.Google Scholar
7. Thase, ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry. 1997;58(9):393–398.Google Scholar
8. Greist, J, McNamara, RK, Mallinckrodt, CH, Rayamajhi, JN, Raskin, J. Incidence and Durations of Antidepressant Nausea:Duloxetine Compared with Parosetine and Fluoxetine. Clin Ther. 2004;26:1446–1455.Google Scholar
9. Thase, ME, Tran, PV, Wiltse, C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005;25(2):132–140.Google Scholar
10. Food and Drug Administration: 2005 Medical Product Safety Alerts. Available at: http://www.fda.gov/medwatch/safety/2005/safety05.htm#Cymbalta. Accessed October 18, 2005.Google Scholar